Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall.
Staphylococcus aureus is responsible for many nosocomial and community-acquired infections. Its evolving resistance to traditional antimicrobial chemotherapy and emerging prevalence outside of the healthcare environment are serious concerns. This review of the changing epidemiology of methicillin-resistant S. aureus, the emergence of vancomycin (glycopeptide)-resistant isolates, and the mechanisms of resistance to beta-lactams and glycopeptides provides an update for clinicians regarding effective strategies for treatment.
Daum
R S
RS
University of Chicago, the Department of Pediatrics, the Section of Pediatric Infectious Diseases, Chicago, IL, USA.
Seal
J B
JB
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000187:drug effects*; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents